Abstract
Audits of adjuvant chemotherapy for breast cancer have revealed that obese patients receive a lower relative dose intensity (RDI). However, interpretation of these studies is complicated by the variable use of cytokine growth factors, empiric dose capping and first cycle dose reductions. We have analysed the impact of obesity on RDI in a cohort of 662 patients that is not confounded by these factors. Patients were classified as overweight or obese on the basis of a body mass index (BMI)>or=25 kg/m2. The mean RDI in patients with BMI>or=25 kg/m2 was actually significantly greater than in those with BMI
| Original language | English |
|---|---|
| Pages (from-to) | 544-8 |
| Number of pages | 5 |
| Journal | European Journal of Cancer |
| Volume | 43 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Feb 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- breast cancer
- myelosuppression
- obesity
- chemotherapy
Fingerprint
Dive into the research topics of 'Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver